Nitinotes
Caesarea, Israel· Est.
Automated endoscopic suturing platform delivering scalable, minimally invasive obesity treatment.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Estimated funding: $30M
AI Company Overview
Automated endoscopic suturing platform delivering scalable, minimally invasive obesity treatment.
ObesityMetabolic disease
Technology Platform
Automated endoscopic suturing system that standardizes suture placement via suction‑assisted tissue capture and single‑button deployment, enabling consistent, high‑density gastric plications.
Opportunities
Regulatory clearance and reimbursement for EndoZip could unlock a multi‑billion‑dollar obesity market, while the automated platform may be adapted for other endoscopic therapeutic procedures.
Risk Factors
Regulatory delays, payer adoption challenges, and competition from established ESG devices could impede commercial rollout.
Competitive Landscape
Key competitors include Apollo Endosurgery and USGI’s ESG platforms; EndoZip differentiates through full automation, reduced learning curve, and consistent suture quality.